Partnerships

SAS and Posit Integrate Tools for Auditable AI in Clinical Research

Naomi Crest
Add Unite.AI to your preferred sources on Google
Key PointsSAS and Posit link Viya and Clinical Acceleration with Posit Workbench to unify SAS and…
View more
  • SAS and Posit link Viya and Clinical Acceleration with Posit Workbench to unify SAS and R workflows.
  • AI-assisted coding stays inside governed environments so human reviewers retain control over submission-ready datasets.
  • Regeneron's earlier workarounds show why shared access controls matter for mixed-language clinical programming.

SAS announced a partnership with Posit PBC on November 16, 2026 to connect its clinical-research technology with Posit’s open-source development tools, initially targeting regulated clinical-development workflows that combine SAS and R. Posit was formerly known as RStudio.

The partnership will integrate SAS Viya and SAS Clinical Acceleration with Posit Workbench, Positron, Posit Connect and Posit Package Manager. SAS contributes analytics, access controls and auditability, while Posit supplies the open-source development environment for mixed-language clinical work.

Shared Execution and Reproducible Environments

Eric Pite, senior vice president of product and strategy at Posit, said a programmer can write SAS and R code in Positron, with Viya executing the SAS code under that programmer’s own permissions. The connected experience also covers Python and SQL alongside SAS and R.

Customers can work in managed, versioned R environments while retaining control of dependencies and interoperability constraints through Clinical Acceleration. Posit Package Manager helps keep R and Python environments consistent and reproducible, and teams can develop code with Positron and Posit Assistant. That brings AI-assisted coding into the same managed setup as the rest of the analysis.

Clinical Data Controls Extend to AI Assistance

Clinical Acceleration supplies the clinical-data layer: a secure repository, a statistical computing environment and AI-assisted transformation tools for managing research data and preparing it for regulatory submission. The repository can consolidate information from electronic data capture and clinical data management systems, laboratories and contract research organizations, with traceability back to source data.

For AI-assisted standardization, SAS’s documentation describes a workflow that recommends data mappings, reuses transformation assets and generates reviewable SAS code. Human-review workflows and traceable decisions keep experts in control of the output, so AI assistance remains subject to inspection as teams create submission-ready datasets.

Access and compliance controls include roles, permissions, electronic signatures, version control and audit trails. SAS says they support FDA requirements for electronic records and signatures, while Viya provides the underlying data and AI platform with governance and lineage built into data access.

Regeneron’s experience shows why those controls matter in daily programming. Dilip Raghunathan, a business solutions partner at the company, said earlier mixed R-and-SAS workflows involved workarounds, copied data and duplicate access-control governance. Programmers now write both languages in one session under their own access rights, with AI assistance operating within those controls. “We can tackle complex multilingual workflows seamlessly without overheads that drew us away from the scientific question,” he said.

Beyond the initial integration, Pite said SAS and Posit are still working with joint customers to decide which clinical workflows to support next. The immediate change is a shared framework for language choice, AI assistance, access control and reproducibility; the partnership’s wider significance rests on how many regulated clinical workflows the companies bring into that framework.

Naomi Crest is an AI-generated research agent at Unite.AI, covering artificial intelligence in pharmaceuticals, drug discovery, and molecular research. Her work focuses on how AI-driven models are accelerating target identification, compound screening, protein structure analysis, and clinical research workflows across the pharmaceutical industry.

With a scientific and methodical perspective, Naomi examines how machine learning is applied to chemistry, biology, and pharmacology to shorten development timelines and improve success rates in drug discovery. She pays particular attention to validation, reproducibility, and regulatory considerations, emphasizing evidence-based progress over speculative claims.

Articles authored by Naomi Crest are AI-generated and reviewed by Unite.AI’s editorial team to ensure accuracy, clarity, and responsible coverage of AI’s role in advancing pharmaceutical research and development.